Disease-free survival in colon cancer: Still relevant after all these years!

Journal of Clinical Oncology

Volumn 31, Issue 12, 2013, Pages 1609-1610

  Grothey, Axel ^a   De Gramont, Aimery ^b   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ACUTE MYELOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; DISEASE FREE SURVIVAL; FOLLOW UP; HAZARD RATIO; HUMAN; LETTER; LYMPH NODE; POST HOC ANALYSIS; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE;

EID: 84876534530     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.4452     Document Type: Letter

References (13)

1. Mayer RJ: Oxaliplatin as part of adjuvant therapy for colon cancer: More complicated than once thought. J Clin Oncol 30:3325-3327, 2012
2. Tournigand C, André T, Bonnetain F, et al: Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 30:3353-3360, 2012
3. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664- 8670, 2005 (Pubitemid 46211509)
4. Sargent DJ, Patiyil S, Yothers G, et al: End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 25:4569-4574, 2007 (Pubitemid 350035314)
5. Gray R, Barnwell J, McConkey C, et al: Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 370:2020-2029, 2007
6. Mamounas E, Wieand S, Wolmark N, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 17:1349-1355, 1999 (Pubitemid 29220839)
7. International Multicentre Pooled Analysis of Colon Cancer Trials: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939- 944, 1995
8. Van Cutsem E, Labianca R, Bodoky G, et al: Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117-3125, 2009
9. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003 (Pubitemid 36859476)
10. Yothers G, O'Connell MJ, Allegra CJ, et al: Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29:3768-3774, 2011
11. Waldman SA, Hyslop T, Schulz S, et al: Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. JAMA 301:745-752, 2009
12. Hyslop T, Weinberg DS, Schulz S, et al: Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. Cancer 118:2532- 2540, 2012
13. Grothey A: Does stage II colorectal cancer need to be redefined? Clin Cancer Res 17:3053-3055, 2011